[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yi Tian\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100604020",false,"NCT07144085","Application of ⁶⁸Ga-FXX489 (NNS309) PET\u002FCT Imaging in Diagnosis of Tumor Diseases.","Inclusion Criteria:\n\n1. Patients with a high suspicion of oncological diseases.\n2. Age: 18-80 years, no gender restriction, able to express themselves independently, and willing to participate in this study with a signed informed consent form.\n\nExclusion Criteria:\n\n1. Failure to sign the informed consent form.\n2. Severe visual or auditory impairment, cognitive disorders, or patients with claustrophobia who cannot communicate effectively.\n3. Severe cardiac dysfunction, cardiac function class III-IV.\n4. Renal failure (serum creatinine level \\> 1.2 mg\u002Fdl).\n5. Allergy to alcohol.\n6. Use of drugs within 1 week prior to the examination that can cause a disulfiram-like reaction with alcohol, such as penicillins, cephalosporins, or cefotetan.\n7. Known pregnancy.","ALL","18 Years","80 Years",{"count":18,"type":19},30,"ESTIMATED","INTERVENTIONAL",[22],"PHASE1","A new radiotracer, 68Ga-FXX489 (NNS309), has been developed for tracking fibroblast activation protein (FAP) and visualizing the tumor stroma. The purpose of the study is to explore the diagnostic value of 68Ga-FXX489 (NNS309) PET\u002FCT imaging in oncological diseases, to assess its safety, imaging characteristics, and biodistribution after administration.",[25,26],"Tumor","Metastatic Cancer",[28,29],"FAP","CAF","RECRUITING","2026-03-30",{"date":33,"type":34},"2026-04-03","ACTUAL",{"date":36,"type":34},"2025-09-11",{"date":38,"type":19},"2027-07-30",{"name":40,"class":41},"Yi Tian","OTHER",""]